Citation Impact
Citing Papers
Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic–Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor
2012
A BOILED‐Egg To Predict Gastrointestinal Absorption and Brain Penetration of Small Molecules
2016 Standout
Cytotoxic Activity of Tivantinib (ARQ 197) Is Not Due Solely to c-MET Inhibition
2013
Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors
2012
Reciprocal Regulation of DUSP9 and DUSP16 Expression by HIF1 Controls ERK and p38 MAP Kinase Activity and Mediates Chemotherapy-Induced Breast Cancer Stem Cell Enrichment
2018 StandoutNobel
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial
2017
Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?
2015
Engineering precision nanoparticles for drug delivery
2020 Standout
Trametinib (GSK1120212) in the treatment of melanoma
2013
Brain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancers
2015
Targeted Therapy for Brain Metastases in EGFR-Mutated and ALK-Rearranged Non-Small-Cell Lung Cancer
2015
Oncology Meets Immunology: The Cancer-Immunity Cycle
2013 Standout
MEK in cancer and cancer therapy
2013
A view on drug resistance in cancer
2019 StandoutNature
ALK alterations in adult renal cell carcinoma: frequency, clinicopathologic features and outcome in a large series of consecutively treated patients
2012
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
2015 Standout
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial
2017
The biology and management of non-small cell lung cancer
2018 StandoutNature
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
2014 Standout
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016 Standout
Classification and mutation prediction from non–small cell lung cancer histopathology images using deep learning
2018 Standout
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
2014 Standout
Zinc-finger proteins in health and disease
2017
Patient-Reported Outcomes and Quality of Life in PROFILE 1007: A Randomized Trial of Crizotinib Compared with Chemotherapy in Previously Treated Patients with ALK-Positive Advanced Non–Small-Cell Lung Cancer
2014
The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence
2015 Standout
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
2016 Standout
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
2017 Standout
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study
2014
Understanding and targeting resistance mechanisms in NSCLC
2017
New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer
2018 Standout
Lung cancer: current therapies and new targeted treatments
2016 Standout
The Evolving Landscape of Brain Metastasis
2018
Cancer-associated cachexia
2018 Standout
Treating ALK-positive lung cancer—early successes and future challenges
2012
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study
2013
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial
2015
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2017 Standout
Targeting apoptosis in cancer therapy
2020 Standout
Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases
2014
Targeting RAS–ERK signalling in cancer: promises and challenges
2014
Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases
2014
The emerging role of MET/HGF inhibitors in oncology
2013
Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer
2012
ALKMolecular Phenotype in Non–Small Cell Lung Cancer: CT Radiogenomic Characterization
2014
Small molecule drug screening in Drosophila identifies the 5HT2A receptor as a feeding modulation target
2013 Standout
The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular Tumours
2016 Standout
Crizotinib in the Treatment of Non–Small-Cell Lung Cancer
2013
Indoles as therapeutics of interest in medicinal chemistry: Bird's eye view
2017 Standout
Acquired resistance to TKIs in solid tumours: learning from lung cancer
2014
Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition
2017
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 Standout
MEK Inhibition in the Treatment of Advanced Melanoma
2013
Radiomics: the bridge between medical imaging and personalized medicine
2017 Standout
Molecular characterization of pulmonary sarcomatoid carcinoma: analysis of 33 cases
2016
Chemical genetic discovery of targets and anti-targets for cancer polypharmacology
2012 Nature
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
2018 Standout
Age-Associated mRNA and miRNA Expression Changes in the Blood-Brain Barrier
2019 StandoutNobel
Prediction of Drug-Drug Interactions with Bupropion and Its Metabolites as CYP2D6 Inhibitors Using a Physiologically-Based Pharmacokinetic Model
2017
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
High circulating hepatocyte growth factor levels associate with epithelial to mesenchymal transition and poor outcome in small cell lung cancer patients
2014
Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design
2018 Standout
ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.
2014
Drug Resistance in HER2-Positive Breast Cancer Brain Metastases: Blame the Barrier or the Brain?
2018
MET As a Possible Target for Non–Small-Cell Lung Cancer
2013
Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine
2015
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study
2015
Lessons Learned From Lung Cancer Genomics: The Emerging Concept of Individualized Diagnostics and Treatment
2013
Breast Cancer Treatment
2019 Standout
EMT, CSCs, and drug resistance: the mechanistic link and clinical implications
2017 Standout
Leptomeningeal disease: current diagnostic and therapeutic strategies
2017
Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastases
2015
Artificial intelligence in cancer imaging: Clinical challenges and applications
2019 Standout
Inhibitors of the anaplastic lymphoma kinase
2012
Targeting Receptor Tyrosine Kinase MET in Cancer: Small Molecule Inhibitors and Clinical Progress
2013
Natural product and natural product derived drugs in clinical trials
2014 Standout
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
2015 Standout
CNS Drug Design: Balancing Physicochemical Properties for Optimal Brain Exposure
2014
ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it.
2014
Targeted therapy for non-small cell lung cancer: current standards and the promise of the future.
2015
NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922
2015
Works of Weiwei Tan being referenced
Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non–Small Cell Lung Cancer
2016
Prediction of Oral Pharmacokinetics of cMet Kinase Inhibitors in Humans: Physiologically Based Pharmacokinetic Model Versus Traditional One-Compartment Model
2010
Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification
2011
ZNF32 contributes to the induction of multidrug resistance by regulating TGF-β receptor 2 signaling in lung adenocarcinoma
2016
Phase I/II dose-finding study of crizotinib (CRIZ) in combination with erlotinib (E) in patients (pts) with advanced non-small cell lung cancer (NSCLC).
2012
Pharmacokinetics (PK) of PF-02341066, a dual ALK/MET inhibitor after multiple oral doses to advanced cancer patients.
2010
CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib
2011
Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement.
2012
Pharmacokinetics (PK) of crizotinib (PF-02341066) in patients with advanced non-small cell lung cancer (NSCLC) and other solid tumors.
2011
Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers
2010